Dallas, TX: ReportsandReports announce it will carry The Funding Landscape for Small Biopharma Ventures, 2010-2015: Trends, strategies and prioritiesMarket Research Report in its Store.
The funding landscape for small and mid-cap biomedical companies has changed enormously over the past two years, driven by recessive public markets and withdrawal of private equity financing. The cost of raising capital has increased, and investors have become very selective about the type of transactions they participate in. Most small biopharma ventures are struggling to raise funds and maintain enough working capital for their clinical endeavours. As with any negative development, there are greater opportunities for both buyers and sellers.
This report investigates the implications of the credit crisis over the next five years and suggests strategies that can improve the chances of raising money without compromising on the inherent strengths of a company or clinical asset. The emerging trends, priorities and strategies of investors are described to help entrepreneurs target the right type of investor and communicate their value proposition in the best possible manner.
Key features of this report
- The long-term and short-term implications of the credit crisis on investors and entrepreneurs seeking to raise funds from public and private markets.
- Established and emerging preferences in the actual deal valuation and execution process- both at a conceptual level and in terms of specific inputs that industry professionals will need. Additional insights on the due-diligence process are also provided.
- Trends associated with “conditional” investments that are better able to share the risks, uncertainties and upsides; especially relevant for alliances between large pharmaceutical companies and smaller biotechnology companies.
- Insights on the negotiations between deal-makers: their focus areas, issues of concern, preferences in risk-sharing and how these preferences are reflected in the actual deal terms and conditions.
Scope of this report
- Facilitate communication between entrepreneurs and investors by appraising them of each others priorities, areas of concern and operational constraints.
- Plan in advance by understanding how such priorities, concerns and constraints will evolve over the next five years.
- Understand the role of large pharmaceutical companies in funding the clinical initiatives of small biopharma players via options-based deal structures that best resolve the conflicting incentives of the two parties.
- Understand the exit strategies of healthcare investors and tailor asset valuations and negotiation points accordingly.
- Use the top-line industry ‘average’ data to shape economic assessments and communication.
Key Market Issues
- IPOs are not around anymore and private equity funds are struggling to raise capital and yesteryear’s artificially suppressed rates. This has severely restricted the funding options for the majority of small-mid cap biopharmaceutical companies.
- Large pharmacutical companies, with their AAA credit ratings and stable cash flows, have become the major source of funds for smaller biotechnology ventures via an array of collaborative arrangements like product licensing, co-development, etc…..
- This situation has greatly improved the bargaining position of the large pharma companies, enabling them to pick and choose from a wide range of relatively lower priced assets to replenish their ailing pipelines.
Key findings from this report
- Existing investors are reinvesting in assets they have already committed funds to because newer investors are demanding excessively dilutive investment structures that do not favor the existing owners.
- Small biotech companies are struggling to maintain working capital reserves as private equity investments have been scaled back and the IPO is no longer a feasible source of funds.
- Both supply and demand-side factors are reducing the earnings potential of biopharma assets. The higher cost of raising capital has fundamentally reduced the capacity to invest in risky drug development assets. Simultaneously, budgetary pressures on healthcare spending are reducing society’s willingness to pay premium prices for therapies that offer marginal improvement.
- Drug manufacturers are likely to become the primary source of funding for small-mid cap biopharma via a variety of established arrangements such a licensing/ marketing agreements, co-development, joint-ventures or M&A.
- The financial crisis has not changed the geographic distribution of venture financing in any discernable manner. The US and Canada will continue to remain the hubs of biopharma innovation in the next five years.
Key questions answered
- How has the financial crisis impacted the funding environment for small-mid sized biomedical companies? What will be the short-term and long-term effects of the crisis for biopharma companies?
- How do healthcare investors value opportunities in early stage biomedical assets? Are there any preferences by investor type in terms of methodologies, discount rates and cash flow projections?
- What are the priorities and preferences of different types of private equity funds? What issues should entrepreneurs prepare answers for to successfully negotiate the due-diligence process of private equity investors?
- How has venture financing changed in response to the credit crisis? Is there a renewed interest in some therapy areas, geographies or stages of the development lifecycle?
Table of Contents
The funding landscape for small biopharma ventures,
Executive Summary 10
Macroeconomic trends and implications 10
Accelerating biopharma collaboration 11
Valuing investment opportunities in small biopharma 12
Priorities and preferences of private investors 13
Top-line trends in venture financing 14
Investment choices of most active firms in 2009 14
Chapter 1 Macroeconomic trends and implications 18
Recent events 19
Supply side factors- higher cost of capital 20
Demand side factors- Decreased earnings potential 21
Provider-level constraints 23
Patient-level implications 25
Short and long term implications 26
Non-dilutive funding in an era of excessive dilution 29
Research grants and government contracts 30
Incentives of non-profit foundations 31
Government incentives and associated initiatives 33
Issues surrounding NDF from non-profit agencies 34
Chapter 2 Accelerating biopharma collaboration 38
Accelerating biopharma collaboration 39
Rapidly evolving deal structures 43
De-risking R&D via options-based investing 44
Due diligence in biopharma alliances 47
Marketing agreement 49
Licensing arrangement/Product acquisition 50
Joint venture 50
Alliance/Corporate partnering 51
Outright acquisition of a company 52
Chapter 3 Valuing investment opportunities in small biopharma 54
Valuation methods and usage 55
Discounted cash flow 56
Risk-adjusted net present value 57
Real options 57
Assessing commercial potential 60
Sales potential 61
Pricing and positioning 62
Cost of commercialization 65
Chapter 4 Priorities and preferences ofprivate investors 68
Stages of investment 69
Investors: definition, overview 72
Distinction between private equity and venture capital funds 72
Angel investors 73
Venture capital funds 74
Mezzanine investors 74
Venture investors versus buyout investors 75
Process of getting new investment 77
Term sheets 78
Type of security 79
Board representation 80
Capital expenditure 83
Single versus multiple investors 84
Investor priorities in the new landscape 85
Market attractiveness and product-market-focus 86
The organization 87
Business plan 88
Assessment of risks 88
Intellectual property protection 89
Chapter 5 Top-line trends in venture financing 92
How to use this chapter 93
Definition of key terms 94
Venture financing 94
Early stage 95
Growth/expansion capital 95
Later stage 95
Bridge loan 96
Private placement 96
Countries attracting the most venture financing 97
Recent trends 98
Distribution of venture financing rounds by investment stage 100
Recent trends 101
Further analysis of financing rounds by stage 103
Chapter 6 Investment choices of most active firms in 2009 108
Most active venture capital investors in 2009 109
Analysis of investment preferences 110
Therapeutic areas of focus 110
Investment destinations by geography 113
Stage of investments 114
Two types of venture investors 115
Corporate Venture Capital (CVC) funds 116
Emerging role of CVC in Life Sciences 116
Strategic motivations 117
Novartis Venture Fund 119
Novo A/S, Denmark 121
Independent venture capital funds 125
SV Life Sciences 125
Investment focus in 2009 125
Texas Coalition for Capital 127
Chapter 7 Appendix 129
Research methodology 129
Browse all Healthcare Market Research Reports
Browse all Business Insights Market Research Reports
Browse all Latest Report
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
7557 Rambler road,
Suite 727, Dallas, TX 75231